Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-20T01:20:21.910Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of Gamma-Vinyl GABA in Friedreich’s Ataxia

Published online by Cambridge University Press:  18 September 2015

Y. De Smet ,
J.Y. Mear ,
G. Tell ,
P.H. Schechter ,
F. Lhermitte  and
Y. Agid
Y. De Smet
Affiliation:
Clinique de Neurologie et neuropsychologie Hôpital de la Salpêtrière, Paris, France and * Centre de recherche Merrell International Strasbourgh, France
J.Y. Mear
Affiliation:
Clinique de Neurologie et neuropsychologie Hôpital de la Salpêtrière, Paris, France and * Centre de recherche Merrell International Strasbourgh, France
G. Tell
Affiliation:
Clinique de Neurologie et neuropsychologie Hôpital de la Salpêtrière, Paris, France and * Centre de recherche Merrell International Strasbourgh, France
P.H. Schechter
Affiliation:
Clinique de Neurologie et neuropsychologie Hôpital de la Salpêtrière, Paris, France and * Centre de recherche Merrell International Strasbourgh, France
F. Lhermitte
Affiliation:
Clinique de Neurologie et neuropsychologie Hôpital de la Salpêtrière, Paris, France and * Centre de recherche Merrell International Strasbourgh, France
Y. Agid
Affiliation:
Clinique de Neurologie et neuropsychologie Hôpital de la Salpêtrière, Paris, France and * Centre de recherche Merrell International Strasbourgh, France
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Gamma-Vinyl GABA, an irreversible inhibitor of GABA-transaminase, was administered orally in two daily doses of 250 mg to 10 patients with cerebellar ataxia (9 with Friedreich’s ataxia, one with olivo-ponto-cerebellar atrophy) for at least one month in an open study. No significant difference occurred in the disability scores of cerebellar symptomatology for the group as a whole, but seven patients showed some improvement in scores with treatment and two patients claimed marked subjective amelioration. Tolerance to Gamma-Vinyl-GABA treatment was excellent. These preliminary results suggest that further studies with well-tolerated agents which enhance CNS GABA-ergic function are warranted in patients with cerebellar ataxia.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 9 , Issue 2 , May 1982 , pp. 171 - 173
Copyright
Copyright © Canadian Neurological Sciences Federation 1982

References

REFERENCES

Bohlen, P., Huot, S. and Pal Freyman, M.G. (1979). The relationship between GABA concentrations in brain and cerebro-spinal fluid. Brain Research 167, 297–305.CrossRefGoogle Scholar
Geoffroy, G., Barbeau, A., Breton, G., Lemieux, B., Aube, M., Leger, C. and Bouchard, J.P. (1976). Clinical description and Roentgenologic Evaluation of Patients with Friedreich’s Ataxia. Can. J. Neurol. Sci. 3, 279–286.CrossRefGoogle ScholarPubMed
Grove, J., Schechter, P.J., Tell, G., Koch-Weser, J., Sjoerdsma, A., Warter, J.M., Marescaux, C., Rumbach, L. (1981). Increased gammaaminobutyric acid (GABA), homocarnosine and β-alanine in cerebro-spinal fluid of patients treated with gamma-vinyl-GABA. Life Sciences, 28, 2431–2439.CrossRefGoogle ScholarPubMed
Huxtable, R.J., Azari, J., Reisine, T., Johnson, P., Yamamura, H.I. and Barbeau, A. (1979). Regional distribution of Amino acids in Friedreich’s Ataxia brains. Can. J. Neurol. Sci. 6, 255–258.CrossRefGoogle ScholarPubMed
Pourcher, E. and Barbeau, A. (1980). Field testing of an Ataxia Scoring and Staging System. Can. J. Neurol. Sci. 7, 339–344.CrossRefGoogle ScholarPubMed